Pill for steroid-resistant graft-versus-host disease after transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new pill called gecacitinib for people whose chronic graft-versus-host disease (a condition where donor cells attack their body after a stem cell transplant) has not gotten better with steroids. The drug aims to control the disease and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell transplant (bone marrow transplant) for a blood disease.
- You have chronic graft-versus-host disease (where donor cells attack your body) that has not improved with steroids or requires daily steroids to control.
- Your blood counts (platelets and white blood cells) are within a safe range without needing growth factor injections.
- Your liver, kidney, and heart function are adequate (no severe organ damage).
- You have no uncontrolled infections, HIV, active hepatitis B or C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the study drug gecacitinib (a JAK inhibitor, which helps control blood cell counts and symptoms) before, during, and after a stem cell transplant improves outcomes for people with myelofibrosis. The goal is to see if it can make the transplant safer and more effective.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.